DOCSLIB.ORG

14 LETTERS to the EDITORS 565 EFFECT of CIMETIDINE on GONADAL FUNCTION in MAN We Were Interested to Read the Paper by Wang Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
14 LETTERS to the EDITORS 565 EFFECT of CIMETIDINE on GONADAL FUNCTION in MAN We Were Interested to Read the Paper by Wang Et Al Br. J. clin. Pharmac. (1982), 14 LETTERS TO THE EDITORS 565 EFFECT OF CIMETIDINE ON GONADAL FUNCTION IN MAN We were interested to read the paper by Wang et al. dine being an antiandrogen in man and this is sup- (1982) which showed that treatment of male patients ported by the finding that cimetidine competes with suffering from duodenal ulcer with cimetidine was androgens for binding to androgen receptors in associated with a significant rise in serum testosterone human skin fibroblasts (Sultan et al., 1980) as it also levels. We are aware of four other published studies does in mouse kidney preparations (Funder & on this topic (including one cited by Wang et al., 1982 Mercer, 1979). (van Thiel et al., 1979)) in patients being treated for Since cimetidine but not ranitidine has this effect acid peptic disorders with cimetidine (Carlson et al., then it is not a function of H2-receptor blockade 1981; Peden et al., 1981; Spona et al., 1981). (Peden et al., 1981). The clinical relevance of this All of these studies showed that treatment with recently became apparent to us when we were cimetidine was associated with a modest rise in basal referred a 50 year old man who had received testosterone levels although this rise was statistically cimetidine 1g/day continuously for 18 months for a significant in only two of the papers (Peden et al., stomal ulcer. He had gynaecomastia and complained 1981; van Thiel et al., 1979). Two of the studies were of impotence. Measurements of serum prolactin, prospective and comparative. That of Carlson et al. gonadotrophins, testosterone and oestradiol-17-,B (1981) found that treatment with cimetidine or ant- were all normal. His therapy was changed to acid was associated with a rise in testosterone while ranitidine. His gynaecomastia is regressing and he our own study comparing cimetidine and ranitidine in rapidly and fully recovered potency (and indeed has 15 patients showed that treatment with cimetidine but acquired non-specific urethritis). not ranitidine was associated with a rise in testo- sterone levels and also with a transient early rise in N.R. PEDEN & K.G WORMSLEY levels of luteinising hormone (Peden et al., 1981). On the basis of previous observations on changes on Department of Pharmacology and Therapeutics, gonadotrophins and testosterone during the use of Ninewells Hospital, Dundee DDJ 9SY antiandrogenic drugs in man (Kliman et al., 1974; Sizonenko et al., 1974) we concluded as have Wang et al. (1982) that our data were compatible with cimeti- Received and accepted June 30, 1982 References CARLSON, H.E., IPPOLITI, A.F. & SWERDLOFF, R.S. Scand., 63,328. (1981). Endocrine effects of acute and chronic cime- SPONA, J., WEISZ, W., RUDIGER, E., HENTSCHEL, E., tidine administration. Dig. Dis and Sci., 26, 428-432. SCHUTZE, K., REICHEL, W., KERSTAN, E., FUNDER, J.W. & MERCER, J.E. (1979). Cimetidine occupies WEWALKA, F. & LOCHS, H. (1981). Hormone serum androgen receptors. J. clin. Endocrinol. Metab., 48, levels during oral cimetidine treatment of patients with 189-191. peptic ulcers. Hepato-Gastroenterol., 28, 165-168. KLIMAN, B., McLAUGHLIN, R., IRWIN, R. & PROUT, G.R. SULTAN, C., TERRAZA, A., DESCOMPS, B. & CRASTES DE (1974). Antiandrogen stimulation of plasma LH and PAULET, A. (1980). Cimetidine competition with testosterone. Clin. Res., 22, 342A. androgens for binding to human sex skin fibroblasts PEDEN, N.R., BOYD, E.J.S., BROWNING, M.C.K., androgen receptors. J. steroid Biochem., 13, 839-840. SAUNDERS, J.H.B. & WORMSLEY, K.G. (1981). Effects VAN THIEL, D.H., GAVALER, J.S., SMITH, W.I. & PAUL, G. of two histamine H2-receptor blocking drugs on basal (1979). Hypothalamic-pituitary-gonadal dysfunction in levels of gonadotrophins, prolactin, testosterone and men using cimetidine. New Engl. J. Med., 300, oestradiol-17,f during treatment of duodenal ulcer in 1012-1015. male patients. Acta Endocrinol., 96, 564-568. WANG, C., LAI, C.L., LAM, K.C. & YEUNG, K.K. (1982). SIZONENKO, P.C., PAUNIER, L. & CUENDET, A. (1974). Effect of cimetidine on gonadal function in man. Br. J. Evaluation of the hypothalamic pituitary gonadal axis by clin. Pharmac., 13, 791-794. a new antiandrogen (SCH 13521) in boys. Acta Paediatr. PYRIDOSTIGMINE IN HUMAN BREAST MILK Cholinesterase inhibitors are still basic therapy for lactating mothers on maintenance therapy with myasthenia gravis and among these pyridostigmine is cholinesterase inhibitors the question often arises most commonly used. In the care of myasthenic whether breast feeding is riskful for the child due to 566 LETTERS TO THE EDITORS Br. J. clin. Pharnwc. (1982),14 transfer of these drugs via the milk. Skoglund et al. according to the method of Aquilonius et al. (1980). (1978), using a quantitative gas liquid chromato- The precision and sensitivity of the assay did not graphic method for pyridostigmine bromide (Chan et differ between plasma and milk. Control experiments al., 1976), were not able to detect this drug in breast were performed to ensure thatphenytoin, ingested by miLk from a treated mother. The development of a one of the mothers (case 1, daily dose 100 mg x 3) or more sensitive and selective analytical procedure has its metabolites did not interfere with the pyridostig- now enabled us to study the plasma and breast milk mine determination. concentrations of pyridostigmine in two nursing mothers.. Case 1 Both women, who gave informed consent, were suffering from myasthenia gravis and had been Plasma and milk samples were collected already 5 treated with oral pyridostigmine (Mestinon®, days after delivery (Table 1). The pyridostigmine Roche) for several years. Treatment was given during concentrations in maternal plasma ranged between 16 the whole pregnancy and lactation periods. Both and 31 ng/ml and similar concentrations were found women gave birth to normal infants, without signs of in the breast milk. Using the milk concentrations neonatal myasthenia. The infants were breast fed found and assuming a daily intake of 150 ml breast without addition of artificial formulas (see further milk per kg body weight, the amount of pyridosti- below). The gain of weight and the development of mine ingested by the nursing infant was calculated to the infants were normal, and there were no signs of about 3 ,ug/kg body weight per day. Since this cor- cholinergic drug effects (salivation, tear flow, gastro- responded to only 0.1% of the dose taken by the intestinal disturbances). mother, i.e. 3 mg/kg body weight, breast-feeding was Blood samples, collected by venipuncture in encouraged. heparinized tubes, were immediately cooled and Plasma and milk samples collected 35 days after plasma was separated by centrifugation and frozen. A delivery, when nursing was well established, showed 10 ml sample of breast milk was obtained by a breast pyridostigmine concentrations similar to those at 5 pump at the beginning of the nursing and immediate- days (Table 1). At 102 days after delivery the mother ly frozen. Plasma and milk samples were assayed for used a lower dose of pyridostigmine and somewhat pyridostigmine concentrations by gas comatography- lower concentrations were found both in plasma and mass spectrometry with deuterated internal standard milk. Table 1 Individual pyridostigmine dosage, time of sample collection and the concentration of pyridostigmnine in maternal plasma, breast milk and infant plasma Sampling time Pyridostigmine concentration (nglml) Daily Days after h after Maternal Breast Milk/plasma Infant dose (a) delivery dose intake plasma milk ratio plasma Case 1 60mg x 3 5 0 16 18 1.13 2 20 4 31 24 0.77 60mg x 3 35 0 17 13 0.76 2 35 3.5 29 17 0.59 6 21 8 16 14 0.88 40mg x 3 102 0 6 x) 2 20 4 14 I 5 0.36 6 10 8 8 x) Case 2 60mg x 5 60 0 62 25 0.40 <2 0.5 100 1.3 85 2.6 60 22 0.37 <2 0.66 + 0.10 Mean + s.e. mean x) = denotes pyridostigmine concentrations of approximately 2-5 ng/ml (a) Only one dose was ingested during the study period. Br. J. clin. Pharmac. (1982), 14 LETTERS TO THE EDITORS 567 Case 2 (Rane & Wilson, 1976). However, in both our cases the amount of pyridostignine per kg body weight Plasma and milk concentrations of pyridostigmine at ingested by the nursing infant was only 0.1% or less of 60 days after delivery are shown in Table 1. The that taken by the mother. It is therefore not astonish- concentrations of pyridostigmine in maternal plasma ing that pyridostigmine was not detectable in infant varied between 60 and 100 ng/ml, and the milk con- plasma, and that there were no signs ofdrug effects in centrations were about 40% of the plasma concentra- the infants. tions. The mother's daily dose was about 5 mg/kg These data indicate that maternal medication with body weight and the calculated daily pyridostigmine pyridostigmine normally is no obstacle to breast- intake of the infant was about 3.5 ,ug/kg body weight. feeding, at least with doses in the range used here The plasma of the infant did not contain detectable (180-300 mg/day). In infants with severely impaired amounts of pyridostigmine, i.e. < 2 ng/ml. renal function caution is recommended. In a previous study ofa nursing woman treated with pyridostigmine, the drug was not detectable in breast The authors are indebted to Mrs Susanne Floberg for milk (Skoglund et al., 1978). The method used, how- skilful technical assistance. ever, was considerably less sensitive than the present one. Despite the relatively low doses and plasma LARS-IVAR HARDELL', BJORN concentrations in the mothers, we were able to detect LINDSTROM;, GUDMAR LONNERHOLMI & pyridostigmine in all breast milk samples.
Load more

Recommended publications
  • Drug-Induced Sexual Dysfunction in Men and Women
    VOLUME 36 : NUMBER 2 : APRIL 2013 ARTICLE Drug-induced sexual dysfunction in men and women Helen M Conaglen whether the clinician is willing to ask about sexual Clinical psychologist and SUMMARY issues and does so in a sensitive way.7,8 Senior research fellow Many medical conditions and their treatments Patients on long-term medications may not be John V Conaglen aware that their sexual problems have developed Endocrinologist and contribute to sexual dysfunction. as a result of their treatment. Conversely some may Associate professor in Commonly implicated drugs include Medicine blame their drugs for sexual problems which are due Sexual Health Research Unit antihypertensives, antidepressants, to relationship difficulties or other stressors. Some Waikato Clinical School antipsychotics and antiandrogens. doctors consider that asking patients if they had Faculty of Medical and Understanding the potential for drug-induced noticed any sexual adverse effects from their drugs Health Sciences University of Auckland sexual problems and their negative impact may ‘suggest’ them to the patient, and possibly result on adherence to treatment will enable the in non-adherence. Patients attributing their sexual clinician to tailor treatments for the patient problems to their drugs are less likely to continue the Key words treatment even when necessary for their health.9 The antidepressants, and his or her partner. consultation should include discussion of the patient’s antihypertensives, Encouraging a discussion with the patient sexual issues so these can be considered in treatment antipsychotics, arousal, about sexual function and providing erectile dysfunction, decisions. hypoactive sexual desire strategies to manage the problem are critical disorder, male impotence, to good clinical care.
    [Show full text]
  • Dative Metabolism of Cortisol in Humans Kunihi
    臨 床 薬 理JPn J Clin Pharmacol Ther 18 (3) Sept 1987 509 Comparison of the Inhibitory Effects of Famotidine and Cimetidine on Hepatic Oxi- dative Metabolism of Cortisol in Humans Kunihiko MORITA* Hiroki KONISHI* Takeshi ONO* and Harumi SHIMAKAWA* (Receivedon Dec.19, 1986) * Hospital Pharmacy, Shiga Universityof Medical Science, Tsukinowa-cho,Seta, Ohtsu520-21, Japan The inhibitory effect of famotidine, a new H2-receptor antagonist, on hepatic oxidative metabolism of cortisol in six healthy volunteers was compared with that of cimetidine by monitoring the change in urinary 6ƒÀ-hydroxycortisol (6ƒÀ-OHF), an oxidative metabolite of cortisol. The ratio of 6ƒÀ-OHF to 17-hydroxycorticosteroids (17-OHCS) in urine was measured before, during, and after treatment with famotidine and cimetidine for 3 days in a cross-over study. The ratio was decreased by 25% -35% of the original level after 1-3 days of oral treatment with cimetidine (800 mg, b. i. d.). The reduction vanished within 2 days after the last dose of cimetidine. The ratio was not significantly changed during oral treatment with famotidine (40 mg, b. i. d.). These findings indicate that famotidine, in contrast to cimetidine, does not affect the hepatic oxidative metabolism of cortisol in man, and it is suggested that famotidine does not affect the hepatic drug-metabolizing capacity in humans. Key words: famotidine, cimetidine, H2-receptor antangonist, 6ƒÀ-hydroxycortisol, enzyme inhibition been shown to inhibit the hepatic elimination of a Introduction number of drugs coadministred.1-4) A number of Cimetidine, a histamine H2-receptor antagonist studies have demonstrated that this inhibitory widely used for the treatment of peptic ulcer, has action of cimetidine is based on its high affinity for cytochrome P-450 in hepatic microsomes *滋 賀医科大学医学部附属病院薬剤部 arising from imidazole and cyano groups.5-7) 〓520-21滋 賀県大津市瀬田月輪町 Ranitidine, an H2-receptor antagonist developed 510 hospital pharmacists, aged 24 to 35 years old (mean 28), participated in the study.
    [Show full text]
  • Auspar Attachment 1. Product Information for Mifepristone
    Attachment 1: Product information for AusPAR MS-2 Step mifepristone/misoprostol MS Health Pty Ltd PM-2013-01037-1-5 Final 13 October 2014. This Product Information was approved at the time this AusPAR was published. PRODUCT INFORMATION - MS-2 StepÔ It is very important that all patients receiving these medications are followed up by a medical practitioner, preferably the prescriber, to ensure that the medication has been effective. Even if no adverse events have occurred all patients must receive follow-up 14 to 21 days after taking mifepristone. Read the SPECIAL WARNINGS AND PRECAUTIONS FOR USE carefully. This document refers to the use of MS-2 StepÔ, which consists of Mifepristone Linepharma 200 mg tablet and GyMiso® misoprostol 200 microgram tablets in combination. These medicines are indicated in females of childbearing age for the medical termination of a developing intrauterine pregnancy, up to 63 days of gestation. The Mifepristone Linepharma 200 mg tablet component of this therapy is also used to treat another condition. For information about the treatment of the other condition, refer to the full Product Information for Mifepristone Linepharma 200 mg tablet individual product (AUST R 175671). NAME OF THE MEDICINE MS-2 StepÔ is a composite pack containing Mifepristone Linepharma 200 mg tablet and GyMiso® misoprostol 200 microgram tablets. Mifepristone Australian Approved Name (AAN): Mifepristone Chemical Structure: CH3 N CH 3 OH CH H CH3 3 H H O Molecular formula: C29H35NO2 Molecular weight: 429.6 Version:22May2014 [63days] Page 1 of 23 Attachment 1: Product information for AusPAR MS-2 Step mifepristone/misoprostol MS Health Pty Ltd PM-2013-01037-1-5 Final 13 October 2014.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Cimetidine Tablets 200Mg, 400Mg and 800Mg
    PACKAGE LEAFLET: INFORMATION FOR THE USER Cimetidine Tablets 200mg, 400mg and 800mg [Cimetidine] Read all of this leaflet carefully before you start ! Are taking other medicines (see Section 'Other taking this medicine because it contains medicines and Cimetidine Tablets '). important information for you. ! Keep this leaflet. You may need to read it again. Other medicines and Cimetidine Tablets ! If you have any further questions, ask your doctor or pharmacist or nurse. Tell your doctor or pharmacist if you are taking, have ! This medicine has been prescribed for you only. recently taken or might take any other medicines. Do not pass it on to others. It may harm them, In particular tell your doctor if you are taking any of even if their signs of illness are the same as the following: yours. ! Anticoagulants to thin your blood e.g. warfarin ! If you get any side effects, talk to your doctor, or ! Anticonvulsants to prevent fits e.g. phenytoin pharmacist or nurse. This includes any possible ! Bronchodilators for breathing difficulties e.g. side effects not listed in this leaflet. See section 4. theophylline ! Anti-arrhythmics to slow heart rate e.g. lidocaine, What is in this leaflet: propranolol 1. What Cimetidine Tablets are and what they ! Antidepressants to treat anxiety e.g. diazepam are used for ! Immunosuppresants to prevent organ rejection 2. What you need to know before you take or rheumatism (e.g. ciclosporin) Cimetidine Tablets ! Medicines that cause a fall in blood cell count 3. How to take Cimetidine Tablets ! Antifungals used to treat fungal infections (e.g. 4.
    [Show full text]
  • Complete Inhibition of Food-Stimulated Gastric Acid Secretion by Combined Application of Pirenzepine and Ranitidine*
    Gut: first published as 10.1136/gut.22.7.542 on 1 July 1981. Downloaded from Gut, 1981, 22, 542-548 Complete inhibition of food-stimulated gastric acid secretion by combined application of pirenzepine and ranitidine* W LONDONG,t V LONDONG, C RUTHE, AND P WEIZERT From the Medizinische Klinik Innenstadt, University ofMunich, Munich, W Germany SUMMARY In a double-blind, placebo controlled and randomised secretory study the effectiveness of pirenzepine, ranitidine, and their combination was compared intraindividually in eight healthy subjects receiving intravenous bolus injections. Pirenzepine (0.15 mg/kg) plus ranitidine (0-6 mg/kg) suppressed peptone-stimulated gastric acid secretion from 69±11 to 2±0-4 mmol H+/3 h; the mean percentage inhibition was 97%. Postprandial gastrin was unaffected. There were only minor side-effects in a few experiments (reduction of salivation, brief blurring of vision), but no prolactin stimulation after ranitidine or ranitidine plus pirenzepine. The combined application of ranitidine and pirenzepine inhibited meal-stimulated acid secretion more effectively and produced fewer side-effects than the combination of cimetidine plus pirenzepine studied previously. The combined application ofclassical anticholinergics Methods and H2-receptor antagonists inhibits basal and http://gut.bmj.com/ stimulated gastric acid secretion in man more than Each subject had four tests which had to be carried either drug alone.' In double-blind, placebo con- out within a fortnight; the interval between two tests trolled and randomised investigations we have was at least three days. On separate days each subject demonstrated79 that combined intravenous bolus received pirenzepine, ranitidine, pirenzepine plus injections ofthe antimuscarinic drug pirenzepine with ranitidine, and placebo in random order by slow cimetidine suppressed peptone-stimulated acid out- intravenous bolus on a double-blind basis according put more effectively (on average by 90%) than either to a predetermined randomisation code.
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use PRASTERA® Safely and Effectively
    PRASTERA- prasterone and ibuprofen Health Science Funding, LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRASTERA® safely and effectively. See full prescribing information for PRASTERA® . PRASTERA® prasterone oral softgels 200mg are for oral use only. Initial U.S. Approval INDICATIONS AND USAGE PRASTERA® prasterone 200 mg oral softgels is indicated in female patients with mild to moderate, active (SLEDAI ≥2) systemic lupus erythematosus (SLE) to restore serum 5-dehydroandrosterone sulfate to levels typical of women without SLE. In Phase III clinical trials in female patients with mild to moderate active SLE, prasterone 200 mg was associated with reduced risk of auto-immune flare, reduced risk of breast cancer and reduced risk of death from any cause. (§§1, 6.2, 6.4, 6.5) DOSAGE AND ADMINISTRATION The recommended dose is one (1) softgel daily. (§2) DOSAGE FORMS AND STRENGTHS 200mg oral softgel capsules supplied in a convenience package with ibuprofen oral tablets 400mg. (§3) CONTRAINDICATIONS Known hypersensitivity to any of its ingredients. (§4) Undiagnosed abnormal genital bleeding. (§4) Known, suspected or history of breast cancer. (§4, §6.5) History of, or known, deep vein thrombosis, pulmonary embolism, arterial thromboembolic disease (e.g., stroke, myocardial infarction). (§4) Hypercholesterolemia or ischemic heart disease. (§4, §7.2.4) Hepatic or renal impairment (pharmacokinetic data lacking). (§4, §7.2) Breast-feeding or known or suspected pregnancy.
    [Show full text]
  • PACKAGE LEAFLET – INFORMATION for the USER Cimetidine
    PACKAGE LEAFLET – INFORMATION FOR THE USER Cimetidine 200mg Tablets Cimetidine 400mg Tablets Cimetidine 800mg Tablets (Cimetidine) Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. In this leaflet: 1. What Cimetidine tablets are and what they are used for 2. What you need to know before you take Cimetidine tablets 3. How to take Cimetidine tablets 4. Possible side effects 5. How to store Cimetidine tablets 6. Contents of the pack and other information 1. What Cimetidine tablets are and what they are used for Cimetidine belongs to a group of medicines called Histamine H2 receptor antagonists and is used as an anti-ulcer drug. It works by reducing the amount of acid in your stomach. Cimetidine is used to treat and relieve the following conditions: Ulcers in the stomach (gastric ulcer) and in upper part of the intestine (duodenum ulcer). Recurrent or stomac ulcers (ulcers that keep coming back or which have occurred following stomach surgery). Ulcers in the stomach or duodenum which may be caused by non-steroidal anti- inflammatory drugs (NSAIDs, often used to reduce pain, fever and inflammation) Acid from the stomach escaping into the food pipe causing pain, inflammation and heartburn (oesophageal reflux).
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    ECOG-ACRIN Operations Office – Boston Frontier Science 900 Commonwealth Avenue Boston, MA 02215 (617) 632-3610 Fax: (617) 632-2990 Randomization: (617) 632-2022 Group Chair: Robert L. Comis, M.D. and Mitchell Schnall, M.D. Jean MacDonald, Director of Research Operations Group Statistician: Robert Gray, Ph.D. and Constantine Gatsonis, Ph.D. Mary Steele, Director of Group Administration July 31, 2014 Martha Kruhm, MS RAC Head, Protocol and Information Office Quality Assurance Section CTEP, DCT, NCI 6130 Executive Blvd, EPN Room 7000 Bethesda, MD 20892 Dear Ms. Kruhm: Enclosed is Addendum #9 to E2809, Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy. The following revisions to E2809 protocol have been made in this addendum: Section Change 1. Cover Page Updated the version date. Inserted into the first and second bullet points the phrase "confirmed on 2. Section 6.1.4 two consecutive additional determinations taken at least 4 weeks apart," to more clearly define undetectable PSA. The following revisions to E2809 Informed Consent Document have been made in this addendum: Section Change 1. Cover Page Updated the version date. "What side effects or Updated the risk section language to correspond with the condensed 2. risks can I expect from risk lists format. being in the study?" "What side effects or 3. risks can I expect from Inserted condensed risk list for Bicalutamide. being in the study?" If you have any questions regarding this addendum, please contact [email protected] or 617-632-3610.
    [Show full text]
  • An Investigation Into the Effects and Possible
    AN INVESTIGATION INTO THE EFFECTS AND POSSIBLE MECHANISMS OF ACTION OF CIMETIDINE AND RANITIDINE ON THE SEXUAL BEHAVIOUR OF MALE RATS BY ROOPRAM BADRI Dip.Med.Tech. (Clin Path); Dip.Med.Tech. (Histopath) Submitted in part fulfilment of the requirements for the degree of Master of Medical Science in the Department of Pharmacology in the Faculty of Health Sciences at the University of Durban-Westville. Supervisor: Professor AL du Preez Joint-Supervisor: Mrs MJ du Preez Date Submitted: June 1985 ACKNOWLEDGEMENTS It is a special pleasure to thank Professor AL du Preez, Rector of Technikon, Natal, (former Head of Pharmacology Department, University of Durban-Westville), who conceived the idea for ' this investigation and offered excellent guidance and constructive criticisms during the course of this study. I am grateful to Mrs MJ du Preez for her encouragement and many valuable suggestions while supervising this research. My sincere thanks are extended to Professor AM Veltman for his kindness and constant encouragement; the late Mr RD Ramkisson for statistical assistance; Professor R Miller and the Pharmacology staff for their assistance in various ways; Mr S Baboolal for writing statistical programs; Mr AI Vawda for assistance with anti androgen studies; Miss I Venkatas for help on use of word processor: and to many colleagues at the University of Ourban-Westville for their generous help. My sincere appreciation goes to Mr HJ Klomfass, Natal Institute of Immunology, for assistance with techniques in ovariectomy and cardiac puncture; Or RH Scott (Department of Pathology), Addington Hospital, for assistance with histology of testes; Or RJ Norman (Department of Chemical Pathology), University of Natal Medical School, for radioimmunoassay of serum testosterone; Mr S Tejram and Mr P Naicker (Department of Medical Illustration), University of Natal Medical School, for photographic assistance.
    [Show full text]
  • Cimetidine | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Cimetidine This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Cimetidine Acid Reducer [OTC] Brand Names: Canada APO-Cimetidine; DOM-Cimetidine [DSC]; MYLAN-Cimetidine [DSC]; NOVO- Cimetine [DSC]; PMS-Cimetidine [DSC] What is this drug used for? It is used to treat or prevent GI (gastrointestinal) ulcers. It is used to treat gastroesophageal reflux disease (GERD; acid reflux). It is used to treat heartburn and sour stomach. It is used to treat syndromes caused by lots of stomach acid. It may be given to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you are taking dofetilide. If you are breast-feeding. Do not breast-feed while you take this drug. Cimetidine 1/6 This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
    [Show full text]